Ibandronate
Metastatic Carcinoma In The Bone
Kelly Fitzgerald, MDSmall moleculePhase 4 / ApprovedActive
BBB
79/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 69/ 100
- Competitive Position
- 95/ 100
Competitive context
32 Active assets in the Metastatic Carcinoma In The Bone cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Denosumab Kelly Fitzgerald, MD | Phase 4 | BBB |
Zoledronate Kelly Fitzgerald, MD | Phase 4 | BBB |
RADIUM RA-223 University of California, San Francisco | Phase 3 | BB |
Zometa Sun Yat-sen University | Phase 4 | BB |
Technetium Tc-99M Cation, Unspecified University of California, San Francisco | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Ibandronate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →